Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
Binding molecules, such as human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, such as H3N2, and have a broad neutralizing activity against such influenza virus. Provided are nucleic acid molecules encoding the antibodies, their sequences and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis and/or treatment of an influenza virus H3N2 infection. The antibodies may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
1. An isolated human binding molecule having neutralizing activity against an influenza virus comprising influenza hemagglutinin protein (HA) of the H3 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
2. The binding molecule of claim 1 , wherein the binding molecule has neutralizing activity against one or more H3N2 strains selected from the group consisting of A/Wisconsin/67/2005, A/Hiroshima/52/2005, A/Panama/2007/99, and A/Johannesburg/33/94.
3. The binding molecule of claim 2 , wherein the binding molecule further has neutralizing activity against H3N2 strain A/Hong Kong/1/68.
4. The binding molecule of claim 1 , wherein the binding molecule is able to prevent, in vitro, trypsin cleavage of H3 HA precursor molecule HA0 into HA1 and HA2.
5. The binding molecule of claim 1 , wherein the binding molecule is able to prevent a conformational change of H3 HA protein required for fusion of the influenza viral membrane with a cell's endosomal membrane.
6. The binding molecule of claim 1 , wherein the binding molecule is not able to bind and neutralize influenza virus A comprising HA of the H1 subtype.
7. An isolated human monoclonal antibody having neutralizing activity against an influenza virus comprising influenza hemagglutinin protein (HA) of the H3 subtype,
wherein the monoclonal antibody is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
8. A pharmaceutical composition comprising:
a human binding molecule having neutralizing activity against an influenza virus comprising influenza hemagglutinin protein (HA) of the H3 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
9. A method of diagnosing in a subject an infection caused by an influenza virus, wherein the method comprises:
contacting a sample from the subject with a diagnostically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine; and
determining whether the binding molecule specifically binds to a molecule in the sample, wherein binding indicates an influenza infection.
10. The binding molecule of claim 1 , wherein the binding molecule has neutralizing activity against an influenza virus comprising HA of H3N2 subtype.
11. An immunoconjugate comprising:
the binding molecule of claim 1 , and
at least one tag.
12. A pharmaceutical composition comprising:
a human binding molecule having neutralizing activity against an influenza virus comprising influenza hemagglutinin protein (HA) of the H3N2 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine; and
a pharmaceutically acceptable excipient.
13. The pharmaceutical composition of claim 12 , further comprising:
at least one additional binding molecule.
14. The pharmaceutical composition of claim 13 , wherein the additional binding molecule(s) are able to neutralize an influenza virus comprising HA of the H1 and/or H5 subtype.
15. A pharmaceutical composition comprising:
at least two influenza virus neutralizing binding molecules, wherein at least one of the influenza virus neutralizing binding molecules is able to neutralize one or more influenza virus subtypes of phylogenetic group 1, and at least one of the influenza virus neutralizing binding molecules is able to neutralize one or more influenza virus subtypes of phylogenetic group 2; and
a pharmaceutically acceptable excipient,
wherein the pharmaceutical composition comprises a human binding molecule having neutralizing activity against an influenza virus comprising influenza hemagglutinin protein (HA) of the H3 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
16. A pharmaceutical composition comprising:
at least one influenza virus neutralizing binding molecules molecule that is able to neutralize an influenza virus comprising influenza hemagglutinin protein (HA) of the H1 and/or H5 subtype; and
a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
17. The binding molecule of claim 1 , wherein the binding molecule is able to specifically recognize and bind an HA protein from influenza virus subtype H3N2.
18. The pharmaceutical composition of claim 14 , wherein the additional binding molecule(s) bind H1N1 and/or H5N1.
19. The human monoclonal antibody of claim 7 , wherein the antibody has neutralizing activity against an influenza virus comprising HA of H3N2 subtype.
20. The human monoclonal antibody of claim 7 , wherein the antibody comprises:
the heavy chain CDR1 region of SEQ ID NO:109, the heavy chain CDR2 region of SEQ ID NO:110, and the heavy chain CDR3 region of SEQ ID NO:111; and
the light chain CDR1 region of SEQ ID NO:1 12, the light chain CDR2 region of SEQ ID NO:113, and the light chain CDR3 region of SEQ ID NO:114.
21. The human monoclonal antibody of claim 7 , wherein the antibody comprises:
the heavy chain CDR1 region of SEQ ID NO:138, the heavy chain CDR2 region of SEQ ID NO:139, and the heavy chain CDR3 region of SEQ ID NO:140; and
the light chain CDR1 region of SEQ ID NO:141, the light chain CDR2 region of SEQ ID NO:142, and the light chain CDR3 region of SEQ ID NO:143.
22. The human monoclonal antibody of claim 7 , wherein the antibody comprises:
the heavy chain CDR1 region of SEQ ID NO:144, the heavy chain CDR2 region of SEQ ID NO:145, and the heavy chain CDR3 region of SEQ ID NO:146; and
the light chain CDR1 region of SEQ ID NO:147, the light chain CDR2 region of SEQ ID NO:148, and the light chain CDR3 region of SEQ ID NO:149.
23. A method of prophylaxing a subject against an infection caused by an influenza virus comprising influenza hemagglutinin protein (HA) of the H3 subtype, wherein the method comprises:
administering to the subject a prophylactically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
24. A method of treating a subject for an infection caused by an influenza virus comprising influenza hemagglutinin protein (HA) of the H3 subtype, wherein the method comprises:
administering to the subject a therapeutically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
25. The binding molecule of claim 1 , wherein the molecule has cross-neutralizing activity against at least an influenza virus comprising HA of the H7 subtype.
26. The human monoclonal antibody of claim 7 , wherein the antibody has cross-neutralizing activity against at least an influenza virus comprising HA of the H7 subtype.
27. A pharmaceutical composition comprising:
a human binding molecule having neutralizing activity against an influenza virus comprising influenza hemagglutinin protein (HA) of the H3 subtype and having cross-neutralizing activity against an influenza virus comprising HA of the H7 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine; and
a pharmaceutically acceptable excipient.
28. A method of prophylaxing a subject against an infection caused by an influenza virus comprising influenza hemagglutinin protein (HA) of the H7 subtype, wherein the method comprises:
administering to the subject a prophylactically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3 subtype and having cross-neutralizing activity against an influenza virus comprising HA of the H7 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
29. A method of treating in a subject an influenza virus infection caused by an influenza virus comprising influenza hemagglutinin protein (HA) of the H10 subtype, wherein the method comprises:
administering to the subject a therapeutically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3 subtype and having cross-neutralizing activity against an influenza virus comprising HA of the H7 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
30. The binding molecule of claim 1 , wherein the molecule has cross-neutralizing activity against at least an influenza virus comprising HA of the H10 subtype.
31. The human monoclonal antibody of claim 7 , wherein the antibody has cross-neutralizing activity against at least an influenza virus comprising HA of the H10 subtype.
32. A pharmaceutical composition comprising:
a human binding molecule having neutralizing activity against an influenza virus comprising influenza hemagglutinin protein (HA) of the H3 subtype and having cross-neutralizing activity against an influenza virus comprising HA of the H10 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine; and
a pharmaceutically acceptable excipient.
33. A method of prophylaxing a subject against an infection caused by an influenza virus comprising influenza hemagglutinin protein (HA) of the H10 subtype, wherein the method comprises:
administering to the subject a prophylactically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3 subtype and having cross-neutralizing activity against an influenza virus comprising HA of the H10 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
34. A method of treating a subject for an infection caused by an influenza virus comprising influenza hemagglutinin protein (HA) of the H10 subtype, wherein the method comprises:
administering to the subject a therapeutically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3 subtype and having cross-neutralizing activity against an influenza virus comprising HA of the H10 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
35. A method of prophylaxing a subject against an infection caused by an influenza virus comprising influenza hemagglutinin protein (HA) of the H3N2 subtype, wherein the method comprises:
administering to the subject a prophylactically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3N2 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
36. A method of treating a subject for an infection caused by an influenza virus comprising influenza hemagglutinin protein (HA) of the H3N2 subtype, wherein the method comprises:
administering to the subject a therapeutically effective amount of a human binding molecule having neutralizing activity against an influenza virus comprising HA of the H3N2 subtype,
wherein the binding molecule is able to specifically recognize and bind an epitope in an uncleaved HA protein (HA0) of subtype H3 having an HA2 polypeptide,
wherein the epitope comprises the amino acids at positions 19, 25, 27, 33, and 34 of the HA2 polypeptide, and
wherein the amino acid at position 19 is aspartic acid, the amino acid at position 25 is arginine, the amino acid at position 27 is glutamine, the amino acid at position 33 is glycine, and the amino acid at position 34 is glutamine.
37. The method of claim 9 , wherein the subject is infected with an influenza virus comprising HA of the H3 subtype.
38. The method of claim 9 , wherein the subject is infected with an influenza virus comprising HA of the H7 subtype, and the binding molecule has cross-neutralizing activity against an influenza virus comprising HA of the H7 subtype.
39. The method of claim 9 , wherein the subject is infected with an influenza virus comprising HA of the H10 subtype, and the binding molecule has cross-neutralizing activity against an influenza virus comprising HA of the H10 subtype.